NASDAQ:MDCX Medicus Pharma Q1 2026 Earnings Report $0.38 +0.01 (+2.59%) Closing price 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.73%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Medicus Pharma EPS ResultsActual EPS-$0.31Consensus EPS -$0.18Beat/MissMissed by -$0.13One Year Ago EPSN/AMedicus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicus Pharma Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsMedicus Pharma's next earnings date is estimated for Monday, August 10, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Medicus Pharma Earnings HeadlinesMedicus Pharma CEO details Teverelix progress – ICYMIJuly 18, 2026 | proactiveinvestors.comMedicus Pharma advances Phase 2 study following FDA and IRB feedbackJuly 18, 2026 | finance.yahoo.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.July 23 at 1:00 AM | Base Camp Trading (Ad)Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approvalJuly 16, 2026 | proactiveinvestors.comMedicus Pharma Receives FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Study in Acute Urinary RetentionJuly 16, 2026 | quiverquant.comQMedicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary RetentionJuly 16, 2026 | globenewswire.comSee More Medicus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicus Pharma and other key companies, straight to your email. Email Address About Medicus PharmaMedicus Pharma (NASDAQ:MDCX), Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer. Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access. Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.View Medicus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip BattleAlphabet Crushed Earnings, But One Number Spooked the MarketPremium Retail’s Stress Test Is Separating Winners From LosersGE Vernova Just Sent a Mixed AI Signal to InvestorsOtis Took Another Guidance Cut—But the Story Isn't OverPhilip Morris Trimmed Guidance, But Its Growth Story Looks UnshakenD-Wave Quantum or a Quantum ETF: Which Is the Better Bet? Upcoming Earnings Verizon Communications (7/24/2026)ENI (7/24/2026)Phillips 66 (7/24/2026)SLB (7/24/2026)American Express (7/24/2026)HCA Healthcare (7/24/2026)Canadian National Railway (7/24/2026)Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
